Cheplapharm and Sanofi Move to Forge Strategic Partnership – Lovenox/Clexane Anchors 20‑Medicine Portfolio and Three‑Site Transfer in Exchange for 26.4 % Equity Stake
Cheplapharm and Sanofi (NASDAQ: SNY) announced their intention to form a strategic partnership, under which Cheplapharm will take over a selection of 20 mature medicines worldwide — including the anticoagulant franchise Lovenox/Clexane (enoxaparin) — and three manufacturing sites from Sanofi. In return, Sanofi will receive a 26.4 % equity stake in Cheplapharm, building on a collaboration between the two companies that began in 2014.
Cheplapharm (Germany, private) and Sanofi (NASDAQ: SNY)
Agreement Type
Intended strategic partnership — portfolio divestiture for equity
Assets Transferred
Selection of 20 mature medicines worldwide, including Lovenox/Clexane (enoxaparin); 3 manufacturing sites
Consideration
26.4 % equity stake in Cheplapharm to Sanofi
Collaboration History
Ongoing since 2014
Deal Value
Not disclosed
Timeline
Commercial transfer from Q1 2027; full close expected by Q3 2027
Portfolio & Manufacturing Assets
Anchor Brand:Lovenox/Clexane (enoxaparin) — a low‑molecular‑weight heparin (LMWH) anticoagulant long used for the prevention and treatment of venous thromboembolism and a historically flagship Sanofi franchise — headlines the 20‑product portfolio.
Portfolio Profile: The transaction covers a selection of mature, established medicines with worldwide scope; the full product list beyond Lovenox/Clexane was not disclosed.
Manufacturing Footprint: Three sites will transfer to Cheplapharm as part of the project:
Site
Location
Employees (approx.)
Csanyikvölgy
Hungary
~400
Jurong
Singapore
~100
Ploërmel
France
~65
Transaction Timeline
Milestone
Timing
Commercial transfer of medicine portfolio begins
Q1 2027
Transfer of manufacturing sites
Following commercial transfer
Expected full close
By Q3 2027
Market Impact & Outlook
For Sanofi: The divestiture advances Sanofi’s continued portfolio sharpening toward innovative, growth‑driven franchises, while the 26.4 % equity stake preserves financial participation in the divested assets and formalizes a decade‑long relationship dating to 2014.
For Cheplapharm: The acquisition materially scales Cheplapharm’s established‑medicines platform — its core business model of stewarding legacy brands — with a globally recognized anchor product in enoxaparin and an expanded manufacturing footprint spanning Europe and Asia.
Workforce Continuity: Approximately 565 employees across the three sites are associated with the transfer, indicating an intent to preserve operational and supply continuity for the divested medicines.
Execution Path: The staged structure — commercial transfer first, manufacturing sites thereafter, closing by Q3 2027 — reflects the complexity of cross‑border carve‑outs spanning product registrations, supply agreements and site separations.
Approvals: The transaction remains an announced intention; customary closing conditions and any regulatory approvals required were not disclosed.
Forward‑Looking Statements This brief contains forward‑looking statements regarding the intended strategic partnership between Cheplapharm and Sanofi, including the transfer of medicines and manufacturing sites, the equity consideration, and the anticipated timeline through Q3 2027. Actual outcomes may differ materially due to risks including definitive documentation, regulatory and antitrust approvals, integration execution, and changes in market conditions.-Fineline Info & Tech
